These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 2019790)

  • 21. Antithrombin activity and disaccharide composition of dermatan sulfate from different bovine tissues.
    Osborne SA; Daniel RA; Desilva K; Seymour RB
    Glycobiology; 2008 Mar; 18(3):225-34. PubMed ID: 18156656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of heparin cofactor II in the modulation of hemostasis.
    Salem HH; Thompson EA
    Dev Biol Stand; 1987; 67():67-72. PubMed ID: 3301469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The second cofactor of heparin].
    Sie P
    Ann Biol Clin (Paris); 1987; 45(2):181-3. PubMed ID: 3619144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits.
    Fernandez FA; Buchanan MR; Hirsh J; Fenton JW; Ofosu FA
    Thromb Haemost; 1987 Jun; 57(3):286-93. PubMed ID: 3116701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective and sustained inhibition of surface-bound thrombin activity by intimatan/heparin cofactor II and its relevance to assessing systemic anticoagulation in vivo, ex vivo and in vitro.
    Buchanan MR; Maclean GA; Brister SJ
    Thromb Haemost; 2001 Sep; 86(3):909-13. PubMed ID: 11583326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
    Buchanan MR; Brister SJ
    Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of heparin cofactor II function by S protein (vitronectin) and formation of a ternary S protein-thrombin-heparin cofactor II complex.
    Preissner KT; Sié P
    Thromb Haemost; 1988 Dec; 60(3):399-406. PubMed ID: 2976993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy.
    Brill-Edwards P; Van Ryn-McKenna J; Cai L; Ofosu FA; Buchanan MR
    Thromb Haemost; 1992 Oct; 68(4):424-7. PubMed ID: 1448774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.
    Andrew M; Mitchell L; Berry L; Paes B; Delorme M; Ofosu F; Burrows R; Khambalia B
    J Clin Invest; 1992 Jan; 89(1):321-6. PubMed ID: 1729278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
    Sheehan JP; Wu Q; Tollefsen DM; Sadler JE
    J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.
    Tollefsen DM; Pestka CA
    J Clin Invest; 1985 Feb; 75(2):496-501. PubMed ID: 3838317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo.
    Van Ryn-McKenna J; Ofosu FA; Gray E; Hirsh J; Buchanan MR
    Ann N Y Acad Sci; 1989; 556():304-12. PubMed ID: 2735661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
    Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
    Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
    Derechin VM; Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin cofactor II modulates the response to vascular injury.
    Tollefsen DM
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):454-60. PubMed ID: 17194895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological actions of sulodexide.
    Ofosu FA
    Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition.
    Hayakawa Y; Hirashima Y; Kurimoto M; Hayashi N; Hamada H; Kuwayama N; Endo S
    FEBS Lett; 2002 Jul; 522(1-3):147-50. PubMed ID: 12095635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.